Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
2.200
0.00 (0.00%)
At close: Jan 2, 2025, 4:00 PM
2.190
-0.010 (-0.45%)
After-hours: Jan 2, 2025, 5:05 PM EST
Esperion Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for ESPR stock have an average target of 7.30, with a low estimate of 2.50 and a high estimate of 16. The average target predicts an increase of 231.82% from the current stock price of 2.20.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ESPR stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 1 | 1 | 1 | 0 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 3 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Initiates $4 | Hold | Initiates | $4 | +81.82% | Dec 18, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $8 | Buy | Initiates | $8 | +263.64% | Dec 17, 2024 |
| Needham | Needham | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +172.73% | Dec 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +627.27% | Dec 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +627.27% | Dec 12, 2024 |
Financial Forecast
Revenue This Year
333.76M
from 116.33M
Increased by 186.90%
Revenue Next Year
437.57M
from 333.76M
Increased by 31.10%
EPS This Year
-0.31
from -2.03
EPS Next Year
0.31
from -0.31
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 365.2M | 698.0M | 1.0B | |||
| Avg | 333.8M | 437.6M | 526.9M | |||
| Low | 304.3M | 353.1M | 326.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 213.9% | 109.1% | 130.1% | |||
| Avg | 186.9% | 31.1% | 20.4% | |||
| Low | 161.6% | 5.8% | -25.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.25 | 1.43 | 2.36 | ||
| Avg | -0.31 | 0.31 | 0.68 | ||
| Low | -0.42 | -0.18 | 0.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 659.4% | ||
| Avg | - | - | 118.9% | ||
| Low | - | - | -84.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.